ATE525401T1 - Vom tumorantigen 5t4 abgeleitete mhc-klasse-i- und ii-peptidantigene - Google Patents

Vom tumorantigen 5t4 abgeleitete mhc-klasse-i- und ii-peptidantigene

Info

Publication number
ATE525401T1
ATE525401T1 AT08015250T AT08015250T ATE525401T1 AT E525401 T1 ATE525401 T1 AT E525401T1 AT 08015250 T AT08015250 T AT 08015250T AT 08015250 T AT08015250 T AT 08015250T AT E525401 T1 ATE525401 T1 AT E525401T1
Authority
AT
Austria
Prior art keywords
mhc class
tumor antigen
peptide antigens
antigens derived
relates
Prior art date
Application number
AT08015250T
Other languages
English (en)
Inventor
Richard Harrop
William Shingler
Susan Kingsman
Original Assignee
Oxford Biomedica Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0509835A external-priority patent/GB0509835D0/en
Priority claimed from GB0516303A external-priority patent/GB0516303D0/en
Application filed by Oxford Biomedica Ltd filed Critical Oxford Biomedica Ltd
Application granted granted Critical
Publication of ATE525401T1 publication Critical patent/ATE525401T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT08015250T 2005-05-13 2006-05-12 Vom tumorantigen 5t4 abgeleitete mhc-klasse-i- und ii-peptidantigene ATE525401T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0509835A GB0509835D0 (en) 2005-05-13 2005-05-13 Peptide
GB0516303A GB0516303D0 (en) 2005-08-08 2005-08-08 Peptide

Publications (1)

Publication Number Publication Date
ATE525401T1 true ATE525401T1 (de) 2011-10-15

Family

ID=37396923

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08015250T ATE525401T1 (de) 2005-05-13 2006-05-12 Vom tumorantigen 5t4 abgeleitete mhc-klasse-i- und ii-peptidantigene

Country Status (7)

Country Link
US (1) US8147838B2 (de)
EP (3) EP1888634A2 (de)
JP (1) JP4926168B2 (de)
AT (1) ATE525401T1 (de)
AU (1) AU2006245512B2 (de)
CA (1) CA2606287A1 (de)
WO (1) WO2006120473A2 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008059252A2 (en) * 2006-11-15 2008-05-22 Oxford Biomedica (Uk) Limited Methods and composition fro t cell receptors which recognize 5t4 antigen
US20090004213A1 (en) 2007-03-26 2009-01-01 Immatics Biotechnologies Gmbh Combination therapy using active immunotherapy
WO2013041687A1 (en) * 2011-09-23 2013-03-28 Amgen Research (Munich) Gmbh Bispecific binding molecules for 5t4 and cd3
AU2012335618A1 (en) * 2011-11-11 2014-06-12 Woomera Therapeutics Antagonists for abnormal vasopressin V2 receptor and uses thereof
AU2018235130B2 (en) 2017-03-15 2023-12-07 Oxford Biomedica (Uk) Limited Method

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0795954B2 (ja) 1982-11-30 1995-10-18 アメリカ合衆国 外来性遺伝子発現のためのポックスウイルス組換え体の製造方法
GB8508845D0 (en) 1985-04-04 1985-05-09 Hoffmann La Roche Vaccinia dna
CA1340203C (en) 1987-09-16 1998-12-15 Noboru Yanagida Recombinant apivoxvirus
DE68923027D1 (de) 1988-03-04 1995-07-20 Cancer Res Campaign Tech Antigene.
AU6075190A (en) 1989-06-30 1991-01-17 Regents Of The University Of California, The Retrovirus detection
US5118672A (en) 1989-07-10 1992-06-02 University Of Georgia Research Foundation 5'-diphosphohexose nucleoside pharmaceutical compositions
DE69133511T2 (de) 1990-08-13 2006-09-28 Isis Pharmaceuticals, Inc., Carlsbad Zuckermodifizierte oligonukleotide zum erkennen und steuern der genexpression
WO1996009400A1 (en) 1994-09-19 1996-03-28 Systemix, Inc. Methods for genetically modifying hematopoietic stem cells
CA2237000A1 (en) 1995-11-08 1997-05-15 The Whitehead Institute For Biomedical Research Stable packaging cell line producing pseudotyped retroviruses
US5739018A (en) 1996-08-07 1998-04-14 The Regents Of The University Of California Packaging cell lines for pseudotyped retroviral vectors
US6133027A (en) 1996-08-07 2000-10-17 City Of Hope Inducible expression system
WO1999061639A2 (en) 1998-05-22 1999-12-02 Oxford Biomedica (Uk) Limited Retroviral delivery system
GB2345063B (en) 1997-09-23 2002-07-24 Oxford Biomedica Ltd Method
GB9720465D0 (en) 1997-09-25 1997-11-26 Oxford Biomedica Ltd Dual-virus vectors
US5965381A (en) 1998-03-06 1999-10-12 Ludwig Institute For Cancer Research Delivery of proteins into eukaryotic cells with recombinant yersinia
BR9910253A (pt) 1998-05-19 2002-09-17 Avidex Ltd Receptor de célula t solúvel
CN1298851C (zh) 1998-11-18 2007-02-07 牛津生物医学（英国）有限公司 多肽
JP2005527180A (ja) * 2001-04-18 2005-09-15 プロテイン デザイン ラブス， インコーポレイテッド 肺がんの診断方法、肺がんの修飾因子の組成及びスクリーニングの方法
GB0203419D0 (en) * 2002-02-13 2002-04-03 Oxford Biomedica Ltd Peptide
GB0203420D0 (en) * 2002-02-13 2002-04-03 Oxford Biomedica Ltd Peptide
NZ539225A (en) 2002-10-09 2006-09-29 Avidex Ltd Single chain recombinant T cell receptors
GB0520067D0 (en) * 2005-10-01 2005-11-09 Cancer Rec Tech Ltd Treatment of cancer

Also Published As

Publication number Publication date
EP2045268B1 (de) 2011-09-21
AU2006245512B2 (en) 2011-12-22
EP2277918A2 (de) 2011-01-26
EP1888634A2 (de) 2008-02-20
US8147838B2 (en) 2012-04-03
WO2006120473A2 (en) 2006-11-16
WO2006120473A3 (en) 2008-03-06
JP2008539752A (ja) 2008-11-20
EP2277918B1 (de) 2012-11-14
EP2045268A1 (de) 2009-04-08
US20090280138A1 (en) 2009-11-12
AU2006245512A1 (en) 2006-11-16
EP2277918A3 (de) 2011-05-11
CA2606287A1 (en) 2006-11-16
JP4926168B2 (ja) 2012-05-09

Similar Documents

Publication Publication Date Title
EA201000207A1 (ru) Новые иммуногенные эпитопы для иммунотерапии
UA103202C2 (ru) Фармацевтическая композиция опухолеассоциированных пептидов и ее применение для лечения раковых заболеваний
CY1114050T1 (el) Μονοκλωνικα αντισωματα εναντι claudin-18 στην αγωγη εναντι καρκινου
EA201590833A1 (ru) Антитела для лечения и профилактики болезни альцгеймера и их применение
MX2009009926A (es) Anticuerpo tumor-especifico humano monoclonal.
ATE451388T1 (de) Tumorassoziierte peptide, die promiskuitiv an humane leukozytenantigen- (hla-) moleküle der klasse ii binden
DOP2013000029A (es) Anticuerpos peptidicos beta amiloide anti-n3pglu y usos de los mismos
CY1118369T1 (el) Αντισωματα εναντι cd38 για την θεραπεια πολλαπλου μυελωματος
CY1111622T1 (el) Ανθρωποποιημενοι ανταγωνιστες anti-cmet
UA109633C2 (uk) Антитіло людини проти тканинного фактора
ATE494303T1 (de) An humane leukozytenantigen-(hla-)klasse-i- oder ii-moleküle bindende tumorassoziierte peptide und damit im zusammenhang stehender impfstoff gegen krebs
EP1844077A4 (de) Dr5-antikörper und deren verwendung
EA201070636A1 (ru) Ингибирование рецептора белка, стимулирующего макрофаги (ron), и способы его лечения
CY1117922T1 (el) Her2/neu-eiδika αντισωματα και μεθοδοι χρησης αυτων
UA105760C2 (uk) Антитіло проти bst2
CY2022028I1 (el) Εξανθρωπισμενα αντισωματα αντι-cd19 και οι χρησεις τους στην θεραπεια ογκων, μεταμοσχευσης και ασθενειων αυτο-ανοσιας
IL163902A0 (en) Antibodies against cancer antigen tmeff2 and uses thereof
DE602005023488D1 (de) Tumorassoziierte antigenprofile in der krebsdiagnostik und immuntherapie
CY1113310T1 (el) Εξανθρωπισμενα αντισωματα ειδικα για nogo-a και φαρμακευτικες χρησεις αυτων
MX2008008185A (es) Antigenos de acido des-n-acetil-sialico, anticuerpos para los mismos, y metodos de uso en la terapia de cancer.
ATE451393T1 (de) Humane anti-idiotypische antikörperfragmente, die her-2/neu ähneln
WO2006120473A3 (en) Mhc class i and ii peptide antigens derived from tumour antigen 5t4
DK1730196T3 (da) EphB4-bindende antistoffer til inhibering af antiogenese og tumorvækst
AU2018256601A1 (en) Use of anti-VEGF antibody in combination with chemotherapy for treating breast cancer
CY1116887T1 (el) Anti-cd19 αντισωματα και χρησεις στην ογκολογια

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties